Bio-Rad Laboratories, Inc. BIO is well-poised for growth in the coming quarters, backed by robust demand in Life Science and Clinical Diagnostics arms. Solid prospects in the blood typing market look ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Long before the genome was mapped, before investors went Internet crazy, even before color television, David and Alice Schwartz started a scientific supply company called Bio-Rad Laboratories. Now, 50 ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These ...